Document is current

Article History

Received: 13 December 2022

Revised: 12 January 2023

Accepted: 12 January 2023

First Online: 13 March 2023

Declarations

:

: AM-V, PAP, IL, LB, EM, AM-Y, SM-Y, and LR-P received honoraria compensation to participate in advisory boards, collaborations as a consultant, and scientific communications, and received research support and funding for travel and congress expenses from Biogen Idec, Novartis, TEVA, BMS, Horizon, Merck Serono, Genzyme, Almirall, Bial, Kern Pharma, Lilly, Sanofi, Bayer, and Roche.

: This study was approved by the Hospital Universitari de Bellvitge Research Ethics Committee, with reference EOM031/22. Patients signed informed consent forms, and data were collected anonymously. Patient information confidentiality was handled in accordance with Spanish regulations.